Safety profile of plasma for fractionation donated in the United Kingdom, with respect to variant Creutzfeldt-Jakob disease.
blood safety
plasma fractionation
prions
vCJD
Journal
Vox sanguinis
ISSN: 1423-0410
Titre abrégé: Vox Sang
Pays: England
ID NLM: 0413606
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
revised:
16
01
2023
received:
21
12
2022
accepted:
07
02
2023
medline:
17
5
2023
pubmed:
8
3
2023
entrez:
7
3
2023
Statut:
ppublish
Résumé
Plasma-derived medicinal products (PDMPs) are life-saving and life-improving therapies, but the raw material is in short supply: Europe depends on importation from countries including the United States. Plasma from donors resident in the United Kingdom has not been fractionated since 1999 when a precautionary measure was introduced in response to the outbreak of variant Creutzfeldt-Jakob disease (vCJD). Cases of vCJD have been far fewer than originally predicted in the 1990s. Since the introduction of leucodepletion in 1999, and accounting for the incubation period, more than 40 million UK-derived blood components have been issued with no reports of TT vCJD. In February 2021, the UK Government authorized manufacture of immunoglobulin from UK plasma. Following separate reviews concluding no significant difference in the risk posed, the United States, Australia, Ireland and Hong Kong also lifted their deferrals of blood donors with a history of living in the United Kingdom. Other countries are actively reviewing their position. Demand is rising for PDMPs, and Europe faces a threat of supply shortages. Industry and patient groups are clear that using UK plasma would bring significant immediate benefits to patients and to the resilience of the European supply chain. From this scientific review, we conclude that UK plasma is safe for fractionation and urge blood regulators and operators to take account of this safety profile when considering fractionation of UK plasma, and to revise their guidelines on the deferral of donors who have lived in, or received a transfusion in, the United Kingdom.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
345-353Informations de copyright
© 2023 International Society of Blood Transfusion.
Références
Prevot J, Jolles S. Global immunoglobulin supply: steaming towards the iceberg? Curr Opin Allergy Clin Immunol. 2020;20:557-64.
Medicines and Healthcare products Regulatory Agency. Critical risk assessment report: use of UK plasma for the manufacture of immunoglobulins and vCJD risk. GOV.UK. [cited 2022 Oct 28]. Available from: https://www.gov.uk/government/publications/critical-risk-assessment-report-use-of-uk-plasma-for-the-manufacture-of-immunoglobulins-and-vcjd-risk/critical-risk-assessment-report-use-of-uk-plasma-for-the-manufacture-of-immunoglobulins-and-vcjd-risk
Therapeutic Goods Administration (TGA). TGA approval to change blood donation rules relating to vCJD deferral. Therapeutic goods administration (TGA). 2022 [cited 2023 Jan 6]. Available from: https://www.tga.gov.au/news/news/tga-approval-change-blood-donation-rules-relating-vcjd-deferral
Food and Drug Administration. Recommendations to reduce the possible risk of transmission of Creutzfeldt-Jakob disease and variant Creutzfeldt-Jakob disease by blood and blood components; Guidance for Industry. [cited 2022 Oct 28]. Available from: https://www.fda.gov/media/124156/download
Irish Blood Transfusion Service. vCJD. [cited 2022 Oct 31]. Available from: https://www.giveblood.ie/can-i-give-blood/keeping-blood-safe/vcjd/
Hong Kong Red Cross Blood Transfusion Service. Recent Changes to Donation Criteria (Updated: 21 Dec 2022). [cited 2023 Jan 6]. Available from: https://www5.ha.org.hk/rcbts/news/news20190310?lang=en
UK Blood Services Forum. UK plasma for fractionation. Review of Safety Profile 2022. Available from: https://www.transfusionguidelines.org/document-library/documents/position-paper-on-uk-plasma-uk-forum-2022/download-file/Position%20paper%20on%20UK%20plasma%20-%20UK%20Forum%202022.pdf
Committee on the Safety of Medicines. Summary of Meeting 1998. [cited 2022 Nov 28]. Available from: https://webarchive.nationalarchives.gov.uk/ukgwa/20140205132315mp_/http:/www.mhra.gov.uk/home/groups/l-cs-el/documents/committeedocument/con003339.pdf
Proposal for a Regulation on substances of human origin. [cited 2022 Oct 31]. Available from: https://health.ec.europa.eu/blood-tissues-cells-and-organs/overview/proposal-regulation-substances-human-origin_en
European Medicines Agency. CHMP position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products. [cited 2022 Dec 5]. Available from: https://www.ema.europa.eu/en/creutzfeldt-jakob-disease-plasma-derived-urine-derived-medicinal-products-scientific-guideline
European Centre for Disease Control and Prevention. The risk of variant Creutzfeldt-Jakob disease transmission via blood and plasma-derived medicinal products. 2021 [cited 2022 Oct 31]. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/vCJD-blood-plasma-amended-version-July-2022-JD.pdf
vCJD transmission by blood components: risk assessment. GOV.UK. [cited 2021 Nov 4]. Available from: https://www.gov.uk/government/publications/vcjd-transmission-by-blood-components-risk-assessment
Salamat MKF, Stewart P, Brown H, Tan KBC, Smith A, de Wolf C, et al. Subclinical infection occurs frequently following low dose exposure to prions by blood transfusion. Sci Rep. 2022;12:10923.
Peden A, McCardle L, Head MW, Love S, Ward HJT, Cousens SN, et al. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia. 2010;16:296-304.
Majeed A, Lehmann P, Kirby L, Knight R, Coleman M. Extent of misclassification of death from Creutzfeldt-Jakob disease in England 1979-1996: retrospective examination of clinical records. BMJ. 2000;320:145-7.
Urwin PJM, Mackenzie JM, Llewelyn CA, Will RG, Hewitt PE. Creutzfeldt-Jakob disease and blood transfusion: updated results of the UK transfusion medicine epidemiology review study. Vox Sang. 2016;110:310-6.
Davidson LRR, Llewelyn CA, Mackenzie JM, Hewitt PE, Will RG. Variant CJD and blood transfusion: are there additional cases? Vox Sang. 2014;107:220-5.
Kanguru L, Logan G, Waddel B, Smith C, Molesworth A, Knight R. A clinicopathological study of selected cognitive impairment cases in Lothian, Scotland: enhanced CJD surveillance in the 65 + population group. BMC Geriatr. 2022;22:603.
Verity C, Winstone AM, Will R, Powell A, Baxter P, de Sousa C, et al. Surveillance for variant CJD: should more children with neurodegenerative diseases have autopsies? Arch Dis Child. 2019;104:360-5.
Health Protection Agency. Fourth case of transfusion-associated variant-CJD. Health Protection Report 2007;1(3) available at https://webarchive.nationalarchives.gov.uk/ukgwa/20140714090249/http://www.hpa.org.uk/hpr/archives/back_issues.htm
National CJD Research and Surveillance Unit. Surveillance. CJD. [cited 2022 Oct 31]. Available from: http://www.cjd.ed.ac.uk/surveillance
Narayan DS, Baker DP, Bellamy PM, Bentley DA, Birchall DJ, Bolton-Maggs DP, et al. Working expert group (WEG) & writing group, on behalf of the SHOT steering group. 2021. Available from: https://www.shotuk.org/wp-content/uploads/myimages/SHOT-REPORT-2021-FINAL-bookmarked-V3-November.pdf
Brandel J-P, Knight R. Chapter 11 - Variant Creutzfeldt-Jakob disease. In: Pocchiari M, Manson J, editors. Handbook of clinical neurology. Elsevier; 2018. p. 191-205.
Etablissement Francais du Sang. Rapport d'Activitie 2020. Etablissement francais du sang. 2021 [cited 2022 Oct 31]. Available from: https://dondesang.efs.sante.fr/qui-sommes-nous
The National CJD Research & Surveillance Unit. Latest Statistics. [cited 2021 Mar 15]. Available from: https://www.cjd.ed.ac.uk/sites/default/files/figs.pdf
Garske T, Ghani AC. Uncertainty in the tail of the variant Creutzfeldt-Jakob disease epidemic in the UK. PLoS One. 2010;5:e15626.
SaBTO. Risk reduction measures for variant Creutzfeldt-Jakob disease: PCWG report. GOV.UK. [cited 2021 Mar 15]. Available from https://www.gov.uk/government/publications/risk-reduction-measures-for-variant-creutzfeldt-jakob-disease-pcwg-report
CHM 27 October 2022 - Final Summary Minutes.pdf. Powered by Box. [cited 2023 Jan 16]. Available from: https://app.box.com/s/jv487awvqzzsrdql0o34h9gg350ceyd4/file/1113226090390
McManus H, Seed CR, Hoad VC, Kiely P, Kaldor JM, Styles CE, et al. Risk of variantCreutzfeldt-Jakobdisease transmission by blood transfusion in Australia. Vox Sang. 2022;117:1016-26.
Grass becomes greener for Australian blood and plasma supplies as thousands of former UK residents step up to donate. Lifeblood. [cited 2022 Oct 28]. Available from: https://www.lifeblood.com.au/news-and-stories/media-centre/media-releases/grass-becomes-greener-australian-blood-and-plasma-supplies
Plasma Protein Therapeutics Association. Lifting of long-time ban on use of UK plasma for manufacturing of immunoglobulins will help patients. Plasma Protein Therapeutics Association. [cited 2022 Oct 28]. Available from: https://www.pptaglobal.org/media-and-information/press-releases/1102-lifting-of-long-time-ban-on-use-of-uk-plasma-for-manufacturing-of-immunoglobulins-will-help-patients
Plasma Protein Therapeutics Association. A missed opportunity to acknowledge EU's dependency on U.S. plasma. Plasma Protein Therapeutics Association. [cited 2022 Nov 1]. Available from: https://www.pptaglobal.org/media-and-information/press-releases/1127-a-missed-opportunity-to-acknowledge-eu-s-dependency-on-u-s-plasma
Defense production act. FEMA.gov. [cited 2022 Dec 14]. Available from: https://www.fema.gov/disaster/defense-production-act
NHS England. Commissioning Criteria Policy for the use of therapeutic Immunoglobulin (Ig) in England. 2021 [cited 2022 Nov 28]. Available from: https://www.england.nhs.uk/publication/commissioning-criteria-policy-for-the-use-of-therapeutic-immunoglobulin-ig-in-england-2021/
Joint Professional Advisory Committee. Guidelines for the blood transfusion and tissue transplantation Services of the United Kingdom. [cited 2022 Oct 28]. Available from: https://transfusionguidelines.org.uk/
Edgeworth JA, Farmer M, Sicilia A, Tavares P, Beck J, Campbell T, et al. Detection of prion infection in variant Creutzfeldt-Jakob disease: a blood-based assay. Lancet. 2011;377:487-93.
Seed CR, Hewitt PE, Dodd RY, Houston F, Cervenakova L. Creutzfeldt-Jakob disease and blood transfusion safety. Vox Sang. 2018;113:220-31.
Foster PR. Assessment of the potential of plasma fractionation processes to remove causative agents of transmissible spongiform encephalopathy. Transfus Med. 1999;9:3-14. Transfus Med Rev. 1999;13:336.
Cai K, Gröner A, Dichtelmüller HO, Fabbrizzi F, Flechsig E, Gajardo R, et al. Prion removal capacity of plasma protein manufacturing processes. Transfusion. 2013;53:1894-905.
Roberts PL, Dalton J, Evans D, Harrison P, Li Z, Ternouth K, et al. Removal of TSE agent from plasma products manufactured in the United Kingdom. Vox Sang. 2013;104:299-308.
Lee DC, Stenland CJ, Miller JLC, Cai K, Ford EK, Gilligan KJ, et al. A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. Transfusion. 2001;41:449-55.
Gregori L, Maring J-A, MacAuley C, Dunston B, Rentsch M, Kempf C, et al. Partitioning of TSE infectivity during ethanol fractionation of human plasma. Biologicals. 2004;32:1-10.
Gröner A, Nowak T, Schäfer W. Pathogen safety of human C1 esterase inhibitor concentrate. Transfusion. 2012;52:2104-12.
Stucki M, Boschetti N, Schäfer W, Hostettler T, Käsermann F, Nowak T, et al. Investigations of prion and virus safety of a new liquid IVIG product. Biologicals. 2008;36:239-47.
Goussen C, Simoneau S, Bérend S, Jehan-Kimmel C, Bellon A, Ducloux C, et al. Biological safety of a highly purified 10% liquid intravenous immunoglobulin preparation from human plasma. BioDrugs. 2017;31:251-61.
Flan B, Arrabal S. Manufacture of plasma-derived products in France and measures to prevent the risk of vCJD transmission: precautionary measures and efficacy of manufacturing processes in prion removal. Transfus Clin Biol. 2007;14:51-62.
Food and Drug Administration. Draft Quantitative Risk Assessment of vCJD Risk Potentially Associated with the Use of Human Plasma-Derived Factor VIII. [cited 2022 Nov 1]. Available from: https://www.fda.gov/media/73877/download
Bellon A, Comoy E, Simoneau S, Mornac S, Dehen C, Perrin A, et al. Decontamination of prions in a plasma product manufacturing environment. Transfusion. 2014;54:1028-36.
European Medicines Agency. Investigation of manufacturing processes for plasma-derived medicinal products with regard to variant Creutzfeldt-Jakob disease risk - scientific guideline. European Medicines Agency. 2018 [cited 2022 Nov 1]. Available from: https://www.ema.europa.eu/en/investigation-manufacturing-processes-plasma-derived-medicinal-products-regard-variant-creutzfeldt
Käsermann F, Kempf C. Sodium hydroxide renders the prion protein PrPSc sensitive to proteinase K. J Gen Virol. 2003;84:3173-6.
Verweij M, Kramer K. Donor blood screening and moral responsibility: how safe should blood be? J Med Ethics. 2018;44:187-91.
Kramer K, Zaaijer HL, Verweij MF. The precautionary principle and the tolerability of blood transfusion risks. Am J Bioeth AJOB. 2017;17:32-43.
Kramer K, Zaaijer HL, Verweij MF. Interpreting and applying the precautionary principle: a response to open peer commentaries on ‘the precautionary principle and the tolerability of blood transfusion risks’. Am J Bioeth AJOB. 2017;17:W4-6.
Kramer K, Verweij MF, Zaaijer HL. Are there ethical differences between stopping and not starting blood safety measures? Vox Sang. 2017;112:417-24.